OZEMPIC
Drug
Novo Nordisk AS
Total Payments
$39,921
Transactions
80
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $39,921 | 80 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $39,921 | 80 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| NN9535-4352 | Novo Nordisk AS | $26,541 | 0 |
| NN9535-4321 | Novo Nordisk AS | $7,483 | 0 |
| NN9535-4416 | Novo Nordisk AS | $4,000 | 1 |
| NN9535-4269 | Novo Nordisk AS | $1,474 | 0 |
| NN9535-4270 | Novo Nordisk AS | $360.00 | 0 |
| NN9535-4506 | Novo Nordisk AS | $63.52 | 0 |
Top Doctors Receiving Payments for OZEMPIC
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Toledo, OH | $35,921 | 79 |
| , DO | Family Medicine | Lilburn, GA | $4,000 | 1 |
Ad
Manufacturing Companies
- Novo Nordisk AS $39,921
Product Information
- Type Drug
- Total Payments $39,921
- Total Doctors 1
- Transactions 80
About OZEMPIC
OZEMPIC is a drug associated with $39,921 in payments to 1 healthcare providers, recorded across 80 transactions in the CMS Open Payments database. The primary manufacturer is Novo Nordisk AS.
Payment data is available from 2019 to 2019. In 2019, $39,921 was paid across 80 transactions to 1 doctors.
The most common payment nature for OZEMPIC is "Unspecified" ($39,921, 100.0% of total).
OZEMPIC is associated with 6 research studies, including "NN9535-4352" ($26,541).